Cookie Consent by PrivacyPolicies.com

Publicaciones científicas

Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma

01-ene-2017 | Revista: Clinical & Translational Oncology

Jiménez-Fonseca P (1), Gómez Saez JM (2), Santamaria Sandi J (3), Capdevila J (4), Navarro Gonzalez E (5), Zafon Llopis C (6), Ramón Y Cajal Asensio T (7), Riesco-Eizaguirre G (8), Grande E (9), Galofré JC (10).

(1) Medical Oncology Service, Hospital Universitario Central de Asturias, Avenida de Roma sn, 33011, Oviedo, Spain.
(2) CIBERDEM, Endocrinology and Nutrition Service, Hospital Universitario de Bellvitge, Barcelona, Spain.
(3)Endocrinology and Nutrition Service, Hospital Universitario de Cruces, Vizcaya, Spain.
(4) Medical Oncology Service, Hospital Universitario de la Vall d'Hebron, Barcelona, Spain.
(5) Endocrinology and Nutrition Service, Hospital Universitario Virgen del Rocio, Sevilla, Spain.
(6) Endocrinology and Nutrition Service, Hospital Universitario de la Vall d'Hebron, Barcelona, Spain.
(7) Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
(8) Endocrinology and Nutrition Service, Hospital Universitario de Móstoles, Madrid, Spain.
(9) Medical Oncology Service, Hospital Universitario Ramón y Cajal, Madrid, Spain.
(10) Endocrinology and Nutrition Service, Clínica Universidad de Navarra, Pamplona, Spain.


Anaplastic thyroid cancer (ATC) is the most aggressive solid tumor and almost uniformly lethal in humans. The Boards of the Thyroid Cancer Group of the Spanish Society of Endocrinology and Nutrition and the Grupo Español de Enfermedades Huérfanas e Infrecuentes of the Spanish Society of Oncology requested that an independent task force draft a more comprehensive consensus statement regarding ATC.

All relevant literature was reviewed, including serial PubMed searches together with additional articles. This is the first, comprehensive Spanish consensus statement for ATC and includes the characteristics, diagnosis, initial evaluation, treatment goals, recommendations and modalities for locoregional and advanced disease, palliative care options, surveillance, and long-term monitoring.

Newer systemic therapies are being investigated, but more effective combinations are needed to improve patient outcomes. Though more aggressive radiotherapy has reduced locoregional recurrences, median overall survival has not improved in more than 50 years.

CITA DEL ARTÍCULO  Clin Transl Oncol. 2017 Jan;19(1):12-20. doi: 10.1007/s12094-016-1506-0. Epub 2016 Apr 5